Project status: ongoing
Inadequate representation in clinical trials risks widening existing disparities in cancer outcomes for underserved populations. Ensuring that trials reflect real‑world patient populations is essential for developing treatments that are equitable, effective, and trusted by all people living with myeloma.
Despite growing recognition of this issue, there is currently no shared European consensus on how best to improve representation in myeloma clinical trials. This project aims to address that gap.
Project aim
This project seeks to identify, assess, and advance practical approaches to improving representation in European myeloma clinical trials. By bringing together existing evidence and the perspectives of key stakeholders, we will develop clear, actionable recommendations to support more inclusive trial design and recruitment across Europe.
Project approach
The project will be delivered in two main stages:
- Scoping literature review
We will conduct a scoping review to map existing frameworks, toolkits, initiatives, and best‑practice guidance designed to support the recruitment of underserved populations into clinical trials. This review will also identify key gaps in knowledge and practice relevant to myeloma and the European context.
The scoping review protocol is publicly available: https://doi.org/10.5281/zenodo.17602138
- Multi stakeholder workshops and recommendation development
Findings from the review will be explored through a series of multi‑stakeholder workshops, assessing their relevance and applicability to myeloma clinical trials in Europe. Working collaboratively with patients, clinicians, researchers, regulators, and industry representatives, we will draft, prioritise, and refine a set of practical, actionable recommendations to improve trial inclusivity.
Get involved
We welcome expressions of interest from individuals and organisations who wish to engage with or contribute to this work. To register your interest, please contact: research@mpeurope.org